Dermatology | Physician's Weekly
Advertisement

Dermatology

Biosimilars Could Cut Spending for Biologic Therapy in the U.S.

Jan 21, 2022

FRIDAY, Jan. 21, 2022 (HealthDay News) -- Biosimilar drugs could drive down prices for biologic drugs and generate savings of about $38.4 billion between 2021 and 2025, according to a study published ...

Non-prescription Moisturizers' Efficacy in Atopic Dermatitis

Jan 21, 2022

For a study, international recommendations proposed twice-daily moisturization as the cornerstone of atopic dermatitis therapy (AD). Moisturizers must be chosen based on their clinical efficacy in enh...

Dupilumab Effect on Laboratory Parameters in Adolescents With Atopic Dermatitis

Jan 21, 2022

For a study, patients with atopic dermatitis (AD) who were taking systemic immunosuppressants, laboratory testing was usually required. A previous analysis of laboratory outcomes in randomized, double...

Baricitinib 2 mg Extended Safety Study in Adults With Atopic Dermatitis

Jan 21, 2022

For a study, it was determined that in the European Union and Japan, baricitinib, a selective Janus kinase 1/Janus kinase 2 inhibitor, was approved for the treatment of moderate-to-severe atopic derma...

In Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis, the Effect of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life

Jan 21, 2022

For a study, atopic dermatitis caused significant patient distress, including itching, sleep disruption, and a reduction in health-related quality of life. Researchers looked at how once-daily oral ab...

A Cross-Sectional Study of 116,816 Patients with Atopic Dermatitis and Celiac Disease

Jan 21, 2022

For a study, it was determined that other immune-mediated illnesses were frequently present in both atopic dermatitis and celiac disease. Researchers had to see if there was a link between atopic derm...

Atopic Dermatitis Treatment with Tralokinumab

Jan 21, 2022

Atopic dermatitis (AD) was a chronic or recurrent heterogeneous inflammatory skin condition with significant economic and social consequences. Alzheimer's disease was a complex illness influenced by a...

Atopic Dermatitis Fabric Selection

Jan 21, 2022

For a study, cotton and silk have long been suggested for atopic dermatitis sufferers because of their purported comfort. New synthetic materials with antimicrobial, anti-inflammatory, moisture-wickin...

Expert Opinions on Key Parameters Influencing Randomized Clinical Trial Interpretation in Moderate-to-Severe Atopic Dermatitis

Jan 21, 2022

For a study, it was determined that treatment of moderate-to-severe atopic dermatitis resulted in novel and developing therapeutic options for the chronic inflammatory skin condition. The fast evoluti...

Adolescents With Uncontrolled Moderate-to-Severe Atopic Dermatitis Show Clinically Significant Responses to Dupilumab

Jan 21, 2022

For a study, it was determined that for teenagers with moderate-to-severe illness, atopic dermatitis was a chronic inflammatory disorder with a significant burden and few therapeutic choices. Signific...

Cannabinoids with Inflammatory and Neoplastic Skin Diseases: What Role Do They Play?

Jan 21, 2022

For a study, it was determined that the endocannabinoid system was a complex and almost ubiquitous network of endogenous ligands, enzymes, and receptors that were triggered by exogenous substances pro...

Ruxolitinib Pharmacokinetics in Atopic Dermatitis Patients Treated With Ruxolitinib Cream

Jan 20, 2022

The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway are involved in the pathogenesis of atopic dermatitis (AD). For topical distribution, a cream formulation of ruxo...

SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, Efficacy and Safety in Patients with Moderate to Severe Atopic Dermatitis

Jan 20, 2022

Atopic dermatitis is a chronic, inflammatory illness that puts sufferers and carers under a lot of stress. SHR0302 is a Janus kinase 1 inhibitor that is being studied for inflammatory skin conditions....

Conjunctivitis in Adolescents with Atopic Dermatitis or Asthma Taking Dupilumab Clinical Trials

Jan 20, 2022

The recognized comorbidity of atopic dermatitis is conjunctivitis. Dupilumab clinical studies in adults with moderate-to-severe atopic dermatitis revealed a greater incidence of conjunctivitis in dupi...

Crisaborole Safety, Efficacy, And Pharmacokinetics in Infants Aged 3 to 24 Months With Mild-to-Moderate Atopic Dermatitis

Jan 20, 2022

For a study, it was determined that crisaborole 2% ointment was a nonsteroidal phosphodiesterase 4 inhibitor used to treat mild to severe atopic dermatitis (AD). For an open-label trial, researchers w...

Adults With Moderate-to-Severe Atopic Dermatitis, Dupilumab Demonstrated Favourable Safety and Sustained Efficacy

Jan 20, 2022

For a study, it was determined that long-term management of moderate-to-severe atopic dermatitis (AD) was prevalent. Researchers were to report on the safety and effectiveness of dupilumab therapy in ...

Specialist-Led Model of Care Can Improve CVD Prevention in Psoriasis

Jan 20, 2022

WEDNESDAY, Jan. 19, 2022 (HealthDay News) -- Dermatologists and patients with psoriatic disease have a positive view of a specialist-led model of care to improve cardiovascular disease (CVD) preventio...

Type 2 Inflammatory Diseases in Pediatric Patients With Atopic Dermatitis

Jan 18, 2022

Contributor   Despite clinical experience and some data suggesting a link between atopic dermatitis (AD) and other atopic morbidities, few studies have investigated the full spectrum of...

Tumour- associated autoantibodies as prognostic cancer biomarkers- a review.

Jan 17, 2022

Throughout the process of carcinogenesis, autologous cells are transformed into cancer cells, leading to changes in their protein expression profiles. It has been suggested that mutations, protein mis...

An injectable superior depot of Telratolimod inhibits post-surgical tumor recurrence and distant metastases.

Jan 17, 2022

The clinical success of Toll-like receptor (TLR) agonists is based on their capacity to efficiently mobilize both innate and adaptive immunity. However, rapid distribution of TLR agonists into the sys...

SUB SPECIALTIES

Advertisement